Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy

Haematologica

Volumn 81, Issue 5, 1996, Pages 434-441

  Cazzola, Mario ^b,c   Ponchio, Luisa ^b   Pedrotti, Claudia ^b   Farina, Giovanna ^b   Cerani, Paola ^b   Lucotti, Claudia ^b   Novella, Annunziata ^b   Rovati, Andrea ^b   Bergamaschi, Gaetano ^b   Beguin, Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF PAVIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Anemia; Erythropoietin; Prediction; Reticulocyte; Transferrin receptor

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ACCURACY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER DIAGNOSIS; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RETICULOCYTE; RETROSPECTIVE STUDY; UREMIA;

ANEMIA; ERYTHROPOIETIN; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS;

EID: 0030324247     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bergström J. New aspects of erythropoietin treatment. J Intern Med 1993; 233:445-62.
2. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 1994; 68:215-23.
3. Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S. Guidelines for the use of recombinant human erythropoietin. Haematologica 1994; 79:526-33.
4. Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992; 79:29-37.
5. Ponchio L, Beguin Y, Farina G, et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 1992; 77:494-501.
6. Beguin Y, Clemons G, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81:1067-76.
7. Schapira L, Antin JH, Ransil BJ, et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990; 76:2354-9.
8. Stenke L, Wallvik J, Celsing F, Hast R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993; 7:1324-7.
9. Ludwig H, Fritz E, Leitgeb C, Percherstorfe, M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-63.
10. Cazzola M, Messinger D, Battistel V, et al. Rrecombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-53.
11. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248:378-81.
12. Wu H, Liu X, Jaemisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59-67.
13. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia. Br J Haematol 1995; 89:831-7.
14. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
15. Martelli M, Ponchio L, Beguin Y, Meloni G, Mandelli F, Cazzola M. Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica 1994; 79:456-9.
16. Beguin Y, Loo M, R'Zik S, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993; 82:2010-6.
17. Beguin Y, Loo M, R'Zik S, et al. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. Br J Haematol 1995; 89:17-23.
18. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoietin-α) therapy in cancer patients. Blood 1995; 85:1676-8.
19. Musto P, Modoni S, Alicino G, et al. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 1994; 79:493-9.